CHL, NS (N = 13) | PMLBCL (N = 16) | p value | Gray zone (N = 3) | ||
---|---|---|---|---|---|
Age | Median (Range) | 26(15–73) | 30 (19–51) | 0.175 | 28 (25–52) |
Sex | Male: Female | 4(30.8%): 9(69.2%) | 6(37.5%): 10(62.5%) | 1.000 | 2: 1 |
Methods of biopsy | Needle: VATS: Open | 6: 3: 4 | 10: 4: 2 | 0: 0: 3 | |
IPI score | High risk (> 3) or low | 7(87.5%): 1(12.5%) | 13(86.7%): 2(13.3%) | 1.000 | 1: 2 |
Ann Arbor stage | I-II: III-IV | 8(80.0%): 2(20.0%) | 10(71.4%): 4(28.5%) | 1.000 | 1: 2 |
LDH | Elevated or not | 4(57.1%): 3(42.9%) | 12(80.0%): 3(20.0%) | 0.334 | 0: 3 |
ECOG score | ≥2 or less | 0: 12(100%) | 0: 14(100%) | 0: 3 | |
Bone marrow | Involved or not | 1(9.1%): 10(90.9%) | 2(13.3%): 13(86.7%) | 1.000 | 0: 3 |
Bulky disease | Yes or No | 6(54.5%): 5(45.5%) | 11(73.3%): 4(26.7%) | 0.419 | 1: 2 |
B symptoms | Yes or No | 5(55.6%): 4(44.4%) | 4(28.6%): 10(71.4%) | 0.383 | 1: 2 |
Follow-up (months) | Median (Range) | 72 (1–116) | 14(1–57) | 48 (14–84) | |
Dead/Alive | 0: 12(100%) | 4(26.7%): 11(73.3%) | 0.106 | 1: 2 | |
Progression | Yes or No | 0: 12(100%) | 6(42.9%): 8(57.1%) | 0.017 | 1: 2 |